Ketotifen/Indomethacin

酮替芬/吲哚美辛

Report date: 2022/03/29 14:07:12

Base Information

Drug NameKetotifen/Indomethacin
Drug Alias NameSJP-002C
ClassificationSmall molecules
Mechanisms of ActionHistamine H1 receptor antagonistsCyclooxygenases inhibitors
TargetsHistamine H1 receptorCyclooxygenases
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNepal
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSen-Jam Pharmaceutical Llc
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A